Blood Res 2014; 49(1):
Published online March 31, 2014
https://doi.org/10.5045/br.2014.49.1.49
© The Korean Society of Hematology
1Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
2Ilam University of Medical Sciences, Ilam, Iran.
Correspondence to : Correspondence to Fatemeh Yari, Ph.D. Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, IBTO bldg, Hemmat. Exp.Way. Next to the Milad Tower, Tehran, Iran, P.O. Box: 14665-1157. Tel: +98-021-82052238, Fax: +98-021-88601555, f.yari@ibto.ir
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Although apoptosis occurs in nucleated cells, studies show that this event also occurs in some anucleated cells such as platelets. During storage of platelets, the viability of platelets decreased, storage lesions were observed, and cells underwent apoptosis. We investigated the effects of caspase-3 inhibitor on the survival and function of platelets after different periods of storage.
Platelet concentrates were obtained from the Iranian Blood Transfusion Organization in plastic blood bags. Caspase-3 inhibitor (Z-DEVD-FMK) was added to the bags. These bags along with control bags to which no inhibitor was added were stored in a shaking incubator at 22℃ for 7 days. The effects of Z-DEVD-FMK on the functionality of platelets were analyzed by assessing their ability to bind to von Willebrand factor (vWF) and to aggregate in the presence of arachidonic acid and ristocetin. Cell survival was surveyed by MTT assay.
At day 4 of storage, ristocetin-induced platelet aggregation was significantly higher in the inhibitor-treated (test) than in control samples; the difference was not significant at day 7. There was no significant difference in arachidonic acid-induced platelet aggregation between test and control samples. However, at day 7 of storage, the binding of platelets to vWF was significantly higher in test than in control samples. The MTT assay revealed significantly higher viability in test than in control samples at both days of study.
Treatment of platelets with caspase-3 inhibitor could increase their functionality and survival.
Keywords Platelet concentrate, Storage, Caspase inhibitor, von Willebrand factor
Blood Res 2014; 49(1): 49-53
Published online March 31, 2014 https://doi.org/10.5045/br.2014.49.1.49
Copyright © The Korean Society of Hematology.
Reza Shiri1,2, Fatemeh Yari1*, Minoo Ahmadinejad1, Shahram Vaeli1, and Mohammad Reza Tabatabaei1
1Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
2Ilam University of Medical Sciences, Ilam, Iran.
Correspondence to: Correspondence to Fatemeh Yari, Ph.D. Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, IBTO bldg, Hemmat. Exp.Way. Next to the Milad Tower, Tehran, Iran, P.O. Box: 14665-1157. Tel: +98-021-82052238, Fax: +98-021-88601555, f.yari@ibto.ir
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Although apoptosis occurs in nucleated cells, studies show that this event also occurs in some anucleated cells such as platelets. During storage of platelets, the viability of platelets decreased, storage lesions were observed, and cells underwent apoptosis. We investigated the effects of caspase-3 inhibitor on the survival and function of platelets after different periods of storage.
Platelet concentrates were obtained from the Iranian Blood Transfusion Organization in plastic blood bags. Caspase-3 inhibitor (Z-DEVD-FMK) was added to the bags. These bags along with control bags to which no inhibitor was added were stored in a shaking incubator at 22℃ for 7 days. The effects of Z-DEVD-FMK on the functionality of platelets were analyzed by assessing their ability to bind to von Willebrand factor (vWF) and to aggregate in the presence of arachidonic acid and ristocetin. Cell survival was surveyed by MTT assay.
At day 4 of storage, ristocetin-induced platelet aggregation was significantly higher in the inhibitor-treated (test) than in control samples; the difference was not significant at day 7. There was no significant difference in arachidonic acid-induced platelet aggregation between test and control samples. However, at day 7 of storage, the binding of platelets to vWF was significantly higher in test than in control samples. The MTT assay revealed significantly higher viability in test than in control samples at both days of study.
Treatment of platelets with caspase-3 inhibitor could increase their functionality and survival.
Keywords: Platelet concentrate, Storage, Caspase inhibitor, von Willebrand factor
Flow cytometry plot. The vWF binding capacity of platelets at the days 4 and 7 of storage.
Table 1 . Comparison of ristocetin and arachidonic acid effects on the aggregation of platelet concentrates (test and control) at the days 4 and 7 of storage (N=15)..
Abbreviations: AA, arachidonic acid; Risto, ristocetin..
Byung Soo Kim, Sang Chul Oh, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim, Chae Seung Lim, Taek Jin Kim
Korean J Hematol 1996; 31(2): 211-217Byung Soo Kim, Jin Ho Park, Sang Won Shin, Yeul Hong Kim, Kap No Lee, Jun Suk Kim, Chae Seung Lim
Korean J Hematol 1995; 30(3): 369-376Chul Won Jung, Jin Seok Ahn, Seonyang Park, Byoung Kook Kim, Noe Kyoung Kim
Korean J Hematol 1994; 29(2): 199-206
Flow cytometry plot. The vWF binding capacity of platelets at the days 4 and 7 of storage.